Ashley L. Lennox
Geron (United States)(US)Gilead Sciences (United States)(US)
Publications by Year
Research Areas
Acute Myeloid Leukemia Research, Telomeres, Telomerase, and Senescence, Advanced biosensing and bioanalysis techniques, Hemoglobinopathies and Related Disorders, Cellular transport and secretion
Most-Cited Works
- → Imetelstat, a novel, first‐in‐class telomerase inhibitor: Mechanism of action, clinical, and translational science(2024)19 cited
- → Population pharmacokinetics of imetelstat, a first‐in‐class oligonucleotide telomerase inhibitor(2024)6 cited
- → Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational Analysis(2025)3 cited
- → P410 Liver involvement in myotubular and centronuclear Myopathy: data from the MTM & CNM patient registry(2023)1 cited
- → Initial Results from the QTc Substudy of the IMerge Phase 3 Trial Demonstrate Clinically Meaningful Efficacy, Manageable Safety, and Absence of Proarrhythmic Risk in Patients with Lower-Risk Myelodysplastic Syndromes Who Received Prior Therapies Beyond Erythropoiesis Stimulating Agents(2024)1 cited
- → Clinical outcomes and safety in patients with lower‐risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial(2025)
- → Myotubular/centronuclear myopathy patient registry: accelerating the pace of research and treatment(2017)
- → No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower‐Risk Myelodysplastic Syndromes(2025)